Literature DB >> 15336440

Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis.

Javier Fernández1, Miguel Navasa, Juan Carlos Garcia-Pagan, Juan G-Abraldes, Wladimiro Jiménez, Jaume Bosch, Vicente Arroyo.   

Abstract

BACKGROUND/AIMS: Albumin administration prevents renal failure and improves survival in spontaneous bacterial peritonitis. This study characterizes the mechanisms of action of albumin in this condition.
METHODS: Systemic and splanchnic hemodynamics, plasma renin activity and plasma concentration of interleukin-6, serum concentration of nitric oxide and ascitic fluid levels of nitric oxide and interleukin-6 were assessed at diagnosis and resolution of infection in 12 patients with spontaneous bacterial peritonitis treated with ceftriaxone plus albumin. At infection resolution there was a significant improvement in circulatory function, as indicated by a significant increase in mean arterial pressure (+8%, P=0.02), a fall in heart rate (-10%, P=0.01), a suppression of plasma renin activity (-67%, P=0.002) and a decrease in creatinine levels. These changes were related to both an increase in cardiac work (stroke work index: +18%, P=0.005) and in peripheral vascular resistance (+14%, P=0.05). The improvement in cardiac function was due to an increase in filling. No significant changes were observed in portal pressure or hepatic blood flow.
CONCLUSIONS: These results indicate that the beneficial effects of albumin administration on systemic hemodynamics and renal function in spontaneous bacterial peritonitis are related to both an improvement in cardiac function and a decrease in the degree of arterial vasodilation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15336440     DOI: 10.1016/j.jhep.2004.05.009

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  25 in total

Review 1.  Gut flora and bacterial translocation in chronic liver disease.

Authors:  John Almeida; Sumedha Galhenage; Jennifer Yu; Jelica Kurtovic; Stephen M Riordan
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

Review 2.  Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.

Authors:  Francesco Salerno; Alexander Gerbes; Pere Ginès; Florence Wong; Vicente Arroyo
Journal:  Gut       Date:  2007-03-27       Impact factor: 23.059

3.  Restricted use of albumin for spontaneous bacterial peritonitis.

Authors:  Samuel H Sigal; Carmen M Stanca; Javier Fernandez; Vicente Arroyo; Miguel Navasa
Journal:  Gut       Date:  2007-04       Impact factor: 23.059

4.  Type of edema in posterior reversible encephalopathy syndrome depends on serum albumin levels: an MR imaging study in 28 patients.

Authors:  A Pirker; L Kramer; B Voller; B Loader; E Auff; D Prayer
Journal:  AJNR Am J Neuroradiol       Date:  2011-01-20       Impact factor: 3.825

Review 5.  Should albumin be used in all patients with spontaneous bacterial peritonitis?

Authors:  Neeraj Narula; Keith Tsoi; John K Marshall
Journal:  Can J Gastroenterol       Date:  2011-07       Impact factor: 3.522

Review 6.  Recent advances in cirrhotic cardiomyopathy.

Authors:  Dimitrios S Karagiannakis; George Papatheodoridis; Jiannis Vlachogiannakos
Journal:  Dig Dis Sci       Date:  2014-11-18       Impact factor: 3.199

Review 7.  Albumin in chronic liver disease: structure, functions and therapeutic implications.

Authors:  Rosaria Spinella; Rohit Sawhney; Rajiv Jalan
Journal:  Hepatol Int       Date:  2015-09-29       Impact factor: 6.047

Review 8.  Renal dysfunction in patients with cirrhosis: Where do we stand?

Authors:  Chrysoula Pipili; Evangelos Cholongitas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-08-06

9.  A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

Authors:  Arun J Sanyal; Thomas Boyer; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Andres Blei; Veit Gülberg; Samuel Sigal; Peter Teuber
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682

Review 10.  Intensive Care Therapy for Patients with Advanced Liver Diseases.

Authors:  Antonios Katsounas; Ali Canbay
Journal:  Visc Med       Date:  2018-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.